JP2021520900A - 膣リングを用いた膣の測定 - Google Patents
膣リングを用いた膣の測定 Download PDFInfo
- Publication number
- JP2021520900A JP2021520900A JP2020555464A JP2020555464A JP2021520900A JP 2021520900 A JP2021520900 A JP 2021520900A JP 2020555464 A JP2020555464 A JP 2020555464A JP 2020555464 A JP2020555464 A JP 2020555464A JP 2021520900 A JP2021520900 A JP 2021520900A
- Authority
- JP
- Japan
- Prior art keywords
- glucose
- sensor
- vaginal
- measured
- measuring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000005259 measurement Methods 0.000 title claims abstract description 25
- 239000006213 vaginal ring Substances 0.000 title claims description 11
- 229940044953 vaginal ring Drugs 0.000 title claims description 10
- 210000001215 vagina Anatomy 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 37
- 210000004877 mucosa Anatomy 0.000 claims abstract description 10
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 230000000975 bioactive effect Effects 0.000 claims abstract description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 129
- 239000008103 glucose Substances 0.000 claims description 126
- 229960001031 glucose Drugs 0.000 claims description 124
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 123
- 239000008280 blood Substances 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 37
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 19
- 229960005309 estradiol Drugs 0.000 claims description 17
- 229930182833 estradiol Natural products 0.000 claims description 17
- 210000003722 extracellular fluid Anatomy 0.000 claims description 17
- 210000000416 exudates and transudate Anatomy 0.000 claims description 17
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 15
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 15
- 229940040129 luteinizing hormone Drugs 0.000 claims description 14
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 229960003387 progesterone Drugs 0.000 claims description 5
- 239000000186 progesterone Substances 0.000 claims description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 102000051325 Glucagon Human genes 0.000 claims description 3
- 108060003199 Glucagon Proteins 0.000 claims description 3
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
- 229960004666 glucagon Drugs 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- 229940005529 antipsychotics Drugs 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229940001447 lactate Drugs 0.000 claims description 2
- 229960003987 melatonin Drugs 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 210000003903 pelvic floor Anatomy 0.000 claims description 2
- 229960002847 prasterone Drugs 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 239000003973 paint Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910000811 surgical stainless steel Inorganic materials 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OVUVNKDANCKDCK-UHFFFAOYSA-N thyronamine Chemical compound C1=CC(CCN)=CC=C1OC1=CC=C(O)C=C1 OVUVNKDANCKDCK-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1107—Measuring contraction of parts of the body, e.g. organ, muscle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4261—Evaluating exocrine secretion production
- A61B5/4294—Evaluating exocrine secretion production vaginal secretions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4318—Evaluation of the lower reproductive system
- A61B5/4337—Evaluation of the lower reproductive system of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2503/00—Evaluating a particular growth phase or type of persons or animals
- A61B2503/40—Animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/22—Ergometry; Measuring muscular strength or the force of a muscular blow
- A61B5/224—Measuring muscular strength
- A61B5/227—Measuring muscular strength of constricting muscles, i.e. sphincters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Endocrinology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
健康な志願者の膣滲出液中のグルコースの測定
概要
この予備研究は、ボーラス溶液を用いてセンサ近くの膣壁を洗浄した場合に、グルコースセンサがグルコース濃度の変化を測定できるか否かを調べるために実施された。また、膣壁と接触するように装置を配置した場合に、膣内からグルコースを測定できるか否かを調べることも重要であった。
装置をNovioSense製塗料でコーティングし、外科用スチール材料でLiGalli製シリコーン膣内リングに取り付け、固定した。コーティングおよび/または組み立ての後、機能化された装置を冷蔵庫に保管した。
異なる濃度のグルコース溶液は、20mMグルコース溶液を生理食塩水(0.9%NaCl溶液)と混合することによって調製した。必要濃度のグルコース溶液を得るために、以下の割合の溶液を混合した。
この試験は、43歳の健康な女性志願者に対して行った。まず、0〜10mMのグルコース溶液を用いて、カテーテルを備えたLiGalli製リング装置を較正した。較正後、装置は、センサが膣壁と接触するように、婦人科医師によって膣内の正しい位置に挿入された。
インビボ予備研究は、グルコースセンサを備えたリング装置が機能することができ、膣液から安定且つ明確な応答を得ることができることを実証した。グルコース濃度(5mMおよび10mM)の増加に対してセンサの即時応答が観察されたため、装置は、グルコース濃度の変化を測定することができる。
[実施例2]
糖尿病患者の膣滲出液中のグルコースの決定
概要
この例の目的は、膣滲出液中のグルコースを測定する膣内装置の能力および有効性を調べることであった。また、この研究は、膣滲出液からサンプリングされたグルコースが、毛細管血液および間質液中のグルコースレベルを反映するか否かを調べるために行われた。
装置のコーティングおよび組み立ては、無菌室で行った。
この試験は、インスリン依存性糖尿病(I型)と診断された23歳の女性志願者に対して行った。較正後、装置は、センサが膣壁と良好に接触するように、婦人科医師によって膣内の正しい位置に挿入された。同時に、15分ごとに毛管血液グルコース値および間質グルコース値を監視した。
測定してから30分後、患者は、インスリンを注射し、昼食を食べた。血液グルコースおよび間質液グルコースの測定値の連続的な増加は、それぞれ45分および60分後観察されたが、膣内センサの電流応答の緩やかな上昇は、75分から検出された。測定開始98分後、患者は、6錠のデキストロース錠剤を服用した。その結果、3つ全ての装置は、見掛けピークに到達するまで測定値の緩やかな増加を示した。ピークに到達した後、測定値は、連続的に低下する。
この実施例は、膣内装置が、最大4.5時間まで、膣内から安定且つ反復可能な信号を測定できることを示した。留意すべきことは、膣粘膜壁に対して配置されたグルコースセンサが安定するのに時間(約30分)を必要とすることである。
[実施例3]
膣滲出液からエストラジオールおよびLHの測定
小さな綿棒で膣粘膜を掻き取った。続いて綿棒を遠心分離し、1μlのサンプル液を回収した。この少量のサンプル液からエストラジオールの濃度を測定するために、PBS溶液を添加し、エストラジオールの存在を測定した。サンプルは、0.082nmol/Lのエストラジオールを含むことが分かった。サンプルを50〜75倍に希釈した。サンプル量が非常に少なく、希釈倍数が高いため、得られた値は非常に精確ではない可能性があるが、いずれにせよ、膣滲出液からエストラジオールを測定できることを証明した。
Claims (13)
- ヒトまたは動物の体内に化合物の存在または生理学パラメータを測定するための方法であって、
前記化合物またはパラメータを測定するためのセンサを備えた膣内リングを膣粘膜と接触するように配置するステップと、
前記センサによって生成された信号を記録するステップとを含む、方法。 - 前記膣リングは、膣滲出液に密接する、請求項1に記載の方法。
- 測定される前記化合物は、グルコース、ラクテート、エストラジオール、プロゲステロン、黄体形成ホルモン(LH)、卵胞刺激ホルモン(FSH)、アンドロステンジオン、コルチゾール、トリヨードチロニン(T3)、チロキシン(T4)、ヨードチラミン(T1a)、チロナミン(T0a)、メラトニン、トロポニン、サイトカイン、テストステロン、デヒドロエピアンドロステロンから選択される、請求項1または2に記載の方法。
- 前記生理学パラメータは、pH、膀胱収縮のような筋肉活動、骨盤底筋の状態または運動性から選択される、請求項1に記載の方法。
- 個体体内の血液グルコースおよび/または間質液グルコース値を決定するための方法であって、
請求項1から3のいずれか一項に記載の方法を含み、
前記センサから得られた値を基準値に相関することによって、対応の血液グルコースおよび/または間質液グルコース値を決定するステップを含む、方法。 - ヒトまたは動物の体内に化合物の投与および測定を併せて実行するための方法であって、
1つ以上の生物活性化合物を投与するステップと、
前記1つ以上の生物活性化合物を投与することによって形成された同様および/または別の化合物の存在および/または濃度および/または生理学パラメータを同時におよび/またはその後に測定するステップとを含み、
前記測定は、膣粘膜と接触するセンサを用いて行われる、方法。 - 前記センサは、膣内リングに設けられる、請求項6に記載の方法。
- 前記1つ以上の生物活性化合物の投与は、前記膣内リングによって行われる、請求項7に記載の方法。
- FSHまたはパルスGnRHを投与する場合、エストラジオールまたはエストラジオール/LHを測定する、請求項6〜8のいずれか一項に記載の方法。
- LHまたはHCGを投与する場合、プロゲステロンを測定する、請求項6〜8のいずれか一項に記載の方法。
- インスリンまたはグルカゴンを投与する場合、グルコースを測定する、請求項6〜8のいずれか一項に記載の方法。
- 抗うつ薬または抗精神病薬を投与する場合、同様の薬物を測定する、請求項6〜8のいずれか一項に記載の方法。
- 前記センサから得られた値は、スマートフォンなどの外部装置に送信される、請求項1〜12に記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18166628 | 2018-04-10 | ||
EP18166628.0 | 2018-04-10 | ||
EP18194034 | 2018-09-12 | ||
EP18194033 | 2018-09-12 | ||
EP18194033.9 | 2018-09-12 | ||
EP18194034.7 | 2018-09-12 | ||
PCT/EP2019/059127 WO2019197486A1 (en) | 2018-04-10 | 2019-04-10 | Vaginal measurements using a vaginal ring |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021520900A true JP2021520900A (ja) | 2021-08-26 |
Family
ID=66102120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020555464A Pending JP2021520900A (ja) | 2018-04-10 | 2019-04-10 | 膣リングを用いた膣の測定 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210113120A1 (ja) |
EP (1) | EP3773199A1 (ja) |
JP (1) | JP2021520900A (ja) |
CN (1) | CN111989041A (ja) |
AU (1) | AU2019250425A1 (ja) |
CA (1) | CA3094260A1 (ja) |
WO (1) | WO2019197486A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016509883A (ja) * | 2013-03-08 | 2016-04-04 | リ・ガリ・ベスローテン・フエンノートシャップLi Galli B.V. | 膣内薬剤送達および/または診断装置 |
US20170079587A1 (en) * | 2015-09-22 | 2017-03-23 | Johnson & Johnson Consumer Inc. | Vaginal ring sensor |
WO2017060299A1 (en) * | 2015-10-06 | 2017-04-13 | Ligalli B.V. | Vaginal drug delivery device and vaginal diagnostic device |
WO2018023037A1 (en) * | 2016-07-29 | 2018-02-01 | Renovia Inc. | Devices, systems, and methods for training pelvic floor muscles |
JP2018509389A (ja) * | 2015-01-30 | 2018-04-05 | リ・ガリ・ベスローテン・フエンノートシャップLi Galli B.V. | 膣用薬物送達デバイス |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7133717B2 (en) * | 1999-08-25 | 2006-11-07 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery and diagnostic sampling |
US20060084848A1 (en) * | 2004-10-14 | 2006-04-20 | Mark Mitchnick | Apparatus and methods for monitoring subjects |
CA2698143C (en) * | 2007-06-26 | 2016-01-19 | Warner Chilcott Company, Llc | Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
US20100274105A1 (en) * | 2009-04-23 | 2010-10-28 | Beth Rosenshein | Body Cavity Physiological Measurement Device |
US9089292B2 (en) * | 2010-03-26 | 2015-07-28 | Medtronic Minimed, Inc. | Calibration of glucose monitoring sensor and/or insulin delivery system |
CN103249348B (zh) * | 2010-07-12 | 2017-07-18 | 瑟拉赛恩传感器股份有限公司 | 用于个体的体内监视的设备和方法 |
WO2012143370A2 (en) | 2011-04-18 | 2012-10-26 | Noviotech B.V. | Biosensor |
CA2906135A1 (en) * | 2013-03-15 | 2014-09-18 | Prometheon Pharma, Llc | Devices, systems, and methods for transdermal delivery of compounds |
GB201311580D0 (en) * | 2013-06-27 | 2013-08-14 | Fertility Focus Ltd | Data analysis system and method |
US20180369391A1 (en) * | 2014-08-06 | 2018-12-27 | Biotime, Inc. | Hydrogel foams and methods of making and using the same |
DE102016200211A1 (de) * | 2016-01-11 | 2017-07-13 | Raumedic Ag | Medikamentenabgabe-Vorrichtung und eine Medikamentenabgabe-Baugruppe |
-
2019
- 2019-04-10 EP EP19716414.8A patent/EP3773199A1/en active Pending
- 2019-04-10 CN CN201980024857.8A patent/CN111989041A/zh active Pending
- 2019-04-10 WO PCT/EP2019/059127 patent/WO2019197486A1/en unknown
- 2019-04-10 JP JP2020555464A patent/JP2021520900A/ja active Pending
- 2019-04-10 US US16/970,183 patent/US20210113120A1/en active Pending
- 2019-04-10 CA CA3094260A patent/CA3094260A1/en active Pending
- 2019-04-10 AU AU2019250425A patent/AU2019250425A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016509883A (ja) * | 2013-03-08 | 2016-04-04 | リ・ガリ・ベスローテン・フエンノートシャップLi Galli B.V. | 膣内薬剤送達および/または診断装置 |
JP2018509389A (ja) * | 2015-01-30 | 2018-04-05 | リ・ガリ・ベスローテン・フエンノートシャップLi Galli B.V. | 膣用薬物送達デバイス |
US20170079587A1 (en) * | 2015-09-22 | 2017-03-23 | Johnson & Johnson Consumer Inc. | Vaginal ring sensor |
WO2017053122A1 (en) * | 2015-09-22 | 2017-03-30 | Johnson & Johnson Consumer Inc. | Vaginal ring sensor |
WO2017060299A1 (en) * | 2015-10-06 | 2017-04-13 | Ligalli B.V. | Vaginal drug delivery device and vaginal diagnostic device |
WO2018023037A1 (en) * | 2016-07-29 | 2018-02-01 | Renovia Inc. | Devices, systems, and methods for training pelvic floor muscles |
Also Published As
Publication number | Publication date |
---|---|
CA3094260A1 (en) | 2019-10-17 |
EP3773199A1 (en) | 2021-02-17 |
CN111989041A (zh) | 2020-11-24 |
WO2019197486A1 (en) | 2019-10-17 |
AU2019250425A1 (en) | 2020-10-08 |
US20210113120A1 (en) | 2021-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6368274B1 (en) | Reusable analyte sensor site and method of using the same | |
US20180049680A1 (en) | Method and system for providing an integrated analyte sensor insertion device and data processing unit | |
US8560059B2 (en) | System and methods for optical sensing and drug delivery using microneedles | |
JP4562920B2 (ja) | 分析物センサを有するホルタ型モニタシステム | |
US9854998B2 (en) | Method and/or system for multicompartment analyte monitoring | |
US20120310063A1 (en) | Real-time self-calibrating sensor system and method | |
CA2715624A1 (en) | Continuous medicament sensor system for in vivo use | |
JP2008529569A (ja) | 移動型医療装置及び医療装置間の通信方法 | |
JP2003502090A (ja) | 検体センサと共に使用するための特性モニタシステム | |
CZ20021820A3 (cs) | Způsob pro automatické sledování koncentrace analytu za použití minimálně invazivních zařízení | |
US20100106140A1 (en) | Assay catheter with pressure monitoring | |
JP6453914B2 (ja) | 皮膚組織中の検体の分圧の断続的な測定 | |
US20190021659A1 (en) | Wireless Medical Evaluation Device | |
JP2006500170A (ja) | 埋込可能型センサ方法及びシステム | |
US20130211372A1 (en) | Body Cavity Physiological Measurement Device | |
TW201012434A (en) | Systems for characterizing physiologic parameters and methods for use therewith | |
US7803128B2 (en) | Needle insertion sensor | |
JP2021520900A (ja) | 膣リングを用いた膣の測定 | |
EP1501405B1 (en) | Needle insertion sensor | |
RU2543293C2 (ru) | Устройство для контроля физиологических параметров человека | |
EP4283294A1 (en) | Method and system for indicating the suitability of administering a labor stimulating drug | |
AU2012203630A1 (en) | Gateway platform for biological monitoring and delivery of therapeutic compounds | |
JPH04150837A (ja) | 血糖測定装置 | |
BRPI0901068A2 (pt) | dispositivo implantável para dosagem e monitoramento em tempo real da glicemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221220 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221223 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240625 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240726 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240809 |